Welcome to our dedicated page for Atea Pharmaceuticals news (Ticker: AVIR), a resource for investors and traders seeking the latest updates and insights on Atea Pharmaceuticals stock.
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) is a clinical-stage biopharmaceutical company focused on oral antiviral therapeutics for serious viral diseases, and its news flow reflects this development-driven profile. Company announcements frequently center on progress in its hepatitis C virus (HCV) program, where Atea is advancing a fixed-dose combination regimen of bemnifosbuvir, a nucleotide analog HCV NS5B polymerase inhibitor, and ruzasvir, an NS5A inhibitor.
News items include updates on the global Phase 3 HCV program, such as enrollment milestones in the C-BEYOND and C-FORWARD trials, expectations for topline results, and details of trial design, endpoints and patient populations. Atea also reports new clinical and nonclinical data, including Phase 2 efficacy results, resistance analyses, pharmacokinetic findings and multiscale modeling that explore the regimen’s antiviral activity, barrier to resistance, relative bioavailability and dosing flexibility.
Investors and observers can also find press releases about Atea’s participation in major medical and investor conferences, including presentations at The Liver Meeting of the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver Congress, as well as appearances at healthcare investment conferences. These communications often highlight new data sets, key opinion leader events and discussions of the HCV commercial landscape.
In addition, Atea’s news coverage includes pipeline expansion updates, notably the development of nucleotide analog candidates AT-587 and AT-2490 for hepatitis E virus (HEV), along with background on the unmet medical need in HEV and the company’s preclinical findings. Financial results releases and business updates, furnished in connection with quarterly reports, provide further context on research and development spending, cash resources and strategic priorities. For those tracking AVIR, this news page offers a centralized view of clinical progress, scientific presentations, pipeline evolution and corporate developments.
Atea Pharmaceuticals (AVIR) provided updates on AT-752, an oral antiviral for dengue fever, during the ASTMH 2022 Annual Meeting. The Phase 1 trial showed that AT-752 was well tolerated at doses up to 1500 mg, achieving plasma levels above the in vitro EC90. The FDA has given Fast Track designation for AT-752, making it a promising option for treating dengue, which affects 400 million annually. Atea is advancing two proof-of-concept studies to evaluate AT-752's safety and efficacy against dengue, aiming to fill the existing treatment gap.
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) will host a live conference call on November 7, 2022, at 4:30 p.m. ET, to report financial results for Q3 2022 and provide a business update. The call can be accessed via registration, with a webcast available in the Investor Relations section of the company's website. Atea focuses on developing oral therapies for severe diseases, particularly targeting ssRNA viruses, including SARS-CoV-2, HCV, dengue, and RSV. The company aims to expand its antiviral pipeline through its proprietary nucleos(t)ide prodrug platform.
Atea Pharmaceuticals (Nasdaq: AVIR) announced that the FDA granted Fast Track Designation to AT-752, an oral antiviral for dengue treatment. This designation aims to expedite development, acknowledging the urgent need for effective treatments as there are currently no approved options. AT-752 has shown promising preclinical activity against dengue and safety in Phase 1 trials. The company is advancing two Phase 2 studies to assess AT-752’s efficacy and safety in adults with dengue virus infections, with initial data expected soon.
Atea Pharmaceuticals (Nasdaq: AVIR) announced a global Phase 3 trial to assess bemnifosbuvir for COVID-19, beginning in Q4 2022. The trial targets high-risk non-hospitalized patients, evaluating bemnifosbuvir as both monotherapy and in combination with other treatments. Previous trials indicated a 71% reduction in hospitalization rates. The randomized, double-blind study aims to enroll 1,500 patients across 300 sites worldwide, focusing on safety and efficacy against various COVID-19 variants. Positive early results emphasize bemnifosbuvir's potential as a cornerstone therapy for COVID-19 treatment.
Atea Pharmaceuticals (Nasdaq: AVIR) announced participation in key investor events on September 13, 2022. The management will host a conference call at 8:30 a.m. ET to detail the global Phase 3 trial of bemnifosbuvir for COVID-19 treatment. Additionally, CEO Jean-Pierre Sommadossi will engage in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference at 12:55 p.m. ET. Live webcasts of these events will be available on Atea's website.
Atea Pharmaceuticals (AVIR) is advancing bemnifosbuvir into late-stage clinical trials for COVID-19 after discussions with the FDA and EMA. New data show bemnifosbuvir retains antiviral activity against the Omicron variant. The company is also enrolling in Phase 2 trials for dengue and preparing for a Phase 2 trial for HCV. Financially, Atea reported a net loss of $31.3 million for Q2 2022, a significant drop from a net income of $1.5 million in Q2 2021, driven by the loss of collaboration revenue from Roche.
Atea Pharmaceuticals (AVIR) announced a live conference call for August 8, 2022, at 4:30 p.m. ET to discuss its Q2 financial results and provide a business update. The company focuses on developing oral antiviral therapies for severe viral diseases, including COVID-19 and hepatitis C. This event will be accessible via registration and a live webcast on their investor relations website. Atea emphasizes its commitment to advancing its nucleos(t)ide prodrug platform for treating RNA viruses. They also caution about risks associated with forward-looking statements.
Atea Pharmaceuticals (Nasdaq: AVIR) announced participation in the William Blair Biotech Focus Conference, with a pre-recorded fireside chat available from July 11, 2022, at 9:00 a.m. ET. The company focuses on developing oral antiviral therapies for severe diseases, utilizing its proprietary nucleos(t)ide prodrug platform. Current efforts include treatments for COVID-19, hepatitis C, dengue, and RSV. Atea emphasizes its commitment to advancing antiviral candidates through ongoing research and development.
Atea Pharmaceuticals (Nasdaq: AVIR) announced that CEO Jean-Pierre Sommadossi will present a corporate overview at the Jefferies Healthcare Conference on June 8, 2022, at 11:00 a.m. ET. A live webcast will be accessible on their website, and a replay will be available for 90 days. Atea is a clinical-stage biopharmaceutical company focused on developing oral antiviral therapies for serious diseases, including COVID-19 and HCV, utilizing its proprietary nucleos(t)ide prodrug platform. The company emphasizes its commitment to addressing unmet medical needs in severe viral infections.
Atea Pharmaceuticals (AVIR) announced new clinical results from the MORNINGSKY trial, indicating a 71% reduction in hospitalization for COVID-19 patients treated with bemnifosbuvir (AT-527) compared to placebo (p=0.047). The Phase 2 study in high-risk patients also showed no deaths among those treated with bemnifosbuvir. The company initiated a Phase 2 global study for AT-752 targeting dengue and is preparing for a combination study of bemnifosbuvir and ruzasvir for hepatitis C in 2H 2022. Atea reported a net loss of $42.1 million for Q1 2022.